Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications

Review

作者: Klionsky, Daniel J ; Bonyadi, Mojtaba ; Nabavi, Noushin ; Salimimoghadam, Shokooh ; Hushmandi, Kiavash ; Reiter, Russel J ; Aref, Amir Reza ; Saadat, Seyed Hassan

Ferroptosis, a recently identified type of non-apoptotic cell death, triggers the elimination of cells in the presence of lipid peroxidation and in an iron-dependent manner. Indeed, ferroptosis-stimulating factors have the ability of suppressing antioxidant capacity, leading to the accumulation of reactive oxygen species (ROS) and the subsequent oxidative death of the cells. Ferroptosis is involved in the pathophysiological basis of different maladies, such as multiple cancers, among which female-oriented malignancies have attracted much attention in recent years. In this context, it has also been unveiled that non-coding RNA transcripts, including microRNAs, long non-coding RNAs, and circular RNAs have regulatory interconnections with the ferroptotic flux, which controls the pathogenic development of diseases. Furthermore, the potential of employing these RNA transcripts as therapeutic targets during the onset of female-specific neoplasms to modulate ferroptosis has become a research hotspot; however, the molecular mechanisms and functional alterations of ferroptosis still require further investigation. The current review comprehensively highlights ferroptosis and its association with non-coding RNAs with a focus on how this crosstalk affects the pathogenesis of female-oriented malignancies, from breast cancer to ovarian, cervical, and endometrial neoplasms, suggesting novel therapeutic targets to decelerate and even block the expansion and development of these tumors.

2023-01-01·Frontiers in endocrinology

The circadian rhythm: an influential soundtrack in the diabetes story.

Review

作者: Prabhakar, Pranav Kumar ; Hariri, Amirali ; Mirian, Mina ; Zarrabi, Ali ; Amini-Pozveh, Maryam ; Aref, Amir Reza ; Sivakumar, Ponnurengam Malliappan ; Kohandel, Mohammad ; Tabatabaee, Aliye

Type 2 Diabetes Mellitus (T2DM) has been the main category of metabolic diseases in recent years due to changes in lifestyle and environmental conditions such as diet and physical activity. On the other hand, the circadian rhythm is one of the most significant biological pathways in humans and other mammals, which is affected by light, sleep, and human activity. However, this cycle is controlled via complicated cellular pathways with feedback loops. It is widely known that changes in the circadian rhythm can alter some metabolic pathways of body cells and could affect the treatment process, particularly for metabolic diseases like T2DM. The aim of this study is to explore the importance of the circadian rhythm in the occurrence of T2DM via reviewing the metabolic pathways involved, their relationship with the circadian rhythm from two perspectives, lifestyle and molecular pathways, and their effect on T2DM pathophysiology. These impacts have been demonstrated in a variety of studies and led to the development of approaches such as time-restricted feeding, chronotherapy (time-specific therapies), and circadian molecule stabilizers.

2022-12-01·Journal of hematology & oncology

Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer

作者: Hushmandi, Kiavash ; Zabolian, Amirhossein ; Gholami, Mohammad Hossein ; Canadas, Israel ; Aref, Amir Reza ; Crea, Francesco ; Kumar, Alan Prem ; Wang, Yuzhuo ; Nabavi, Noushin ; Hashemi, Farid ; Ashrafizadeh, Milad ; Zarrabi, Ali ; Mirzaei, Sepideh

项与 Xsphera Biosciences, Inc. 相关的新闻（医药）

2023-11-14

·BioSpace

Xsphera Biosciences and NEX-I Collaborate to Advance Oncology Drug Research

Boston, MA – Xsphera Biosciences, a leading biotechnology company specializing in ex vivo testing of oncology therapeutics on patient-excised tumor tissue, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics. This partnership represents a significant step forward in oncology drug research and development. At the heart of this partnership lies Xsphera's innovative technology, exclusively licensed from the Dana-Farber Cancer Institute. Xsphera’s technology maintains each patient’s tumor microenvironment in an ex vivo platform directly from a fresh excisional tumor biopsy. Over the past year, Xsphera has played a pivotal role in advancing NEX-I’s pipeline by assessing the performance of NEX-I mono and combination therapies on patient tumor samples. Additionally, the companies have leveraged Xsphera’s cloud analytics platform to jointly explore molecular pathways modulated by the multiple therapeutic treatments, aiming to comprehend the mechanisms of action and resistance for each treatment across a diverse set of patient samples. NEX-I is advancing the development of 'NXI-101', a notable first-in-class antibody drug targeting 'ONCOKINE-1', a factor produced by cancer cells that contributes to the resistance of cancer cells to cancer immunotherapy. With treatments like NXI-101 designed to counter these resistance factors, NEXI aims to bolster the efficacy of cancer immunotherapy. Furthermore, NEX-I is diligently working to expedite its entry into global clinical markets. Stephen Remondi, CEO of Xsphera Biosciences, remarked, "This MOU underscores our shared commitment to deepen our collaboration. We are excited to further our understanding of immune modulation in response to NEX-I therapeutics as well as to discover new therapeutic targets in oncology that is enabled by comparing the modulated responses of different therapeutics on tumor tissue from the same patient. " Importantly, this partnership is set to deliver tangible benefits to cancer patients by tailoring treatments to their unique biological responses, thereby improving treatment outcomes and personalizing the battle against cancer." CEO, Kyoung Wan Yoon, stated, “NXI-101 is on the verge of entering clinical trials next year. On top of our animal data, validating the efficacy and mechanism of NXI-101 through our collaborative research with Xsphera increases our likelihood of clinical success, and will deliver real-world value to patients. Furthermore, through this research collaboration, we aim to verify the possibility of developing companion diagnostic biomarkers for the NXI-101 treatment and accelerate the pace of technological and business growth globally." About Xsphera Biosciences: Xsphera Biosciences is a biotechnology company dedicated to bridging the translational gap between animal models and human clinical trials for oncology therapeutics. Through collaboration with Dana-Farber, Xsphera has developed a revolutionary fresh human tumor tissue-based platform that enables the assessment of therapeutic efficacy across various cancer indications and drug modalities. Integrating this ex vivo biology capability with its AI-powered cloud analytics platform, Xsphera can reveal the underlying mechanisms of action and resistance in the tumor microenvironment, providing invaluable insights into human biology and clinical trial strategy. For more information, please visit the Xsphera website at . About NEX-I: NEX-I is breaking ground in the fight against cancer with its next-generation therapies targeting immunotherapy-resistant cancers. Leveraging its proprietary platform, NEX-I has developed robust models for immunotherapy-refractory cancers to analyze their characteristics and identify novel therapeutic targets comprehensively. This unique and dedicated research has led to the discovery of a series of soluble targets, ONCOKINE, which highly expresses and plays a critical role in refractory cellular mechanisms through the proprietary screening platform. NEX-I proposes a new standardized solution to inhibit cancer cell growth and metastasis by suppressing them. Learn more at . A copy of the White Paper describing NXI-101 and the results from Xsphera platform can be found here: For further information, please contact: Xsphera Biosciences Inc. Kazuhito Ishikawa Vice President, Sales and Business development kazu@xspherabio.com

免疫疗法

100 项与 Xsphera Biosciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Xsphera Biosciences, Inc. 相关的转化医学

登录后查看更多信息